This association makes anti-EGFR agents also good targeting probes, with several works reporting the conjugated use of several anti-EGFR antibodies, such as the commercial Cetuximab (CTX), with therapeutic molecules (drugs, pro-drugs, etc.)and nanometric vectors for either diagnosis or therapeutics in CRC [31,32,33]. Here, EGFR is linked to colorectal carcinoma.